Avalyn Pharma (NASDAQ:AVLN) Stock Price Down 5.1% - Here's What Happened

Key Points

• Avalyn Pharma shares fell 5.1% to $26.69 in midday trading, while volume dropped 71% below the average daily level.
• Analyst views remain mixed: Wall Street Zen and Weiss Ratings issued sell assessments, while Morgan Stanley and Raymond James maintained bullish views. The stock has a consensus “Moderate Buy” rating and a $60 average price target.
• The clinical-stage biopharmaceutical company slightly beat quarterly EPS estimates, reporting a loss of $0.98 per share versus the expected $1.03 loss. Several institutional investors, including Montanova Capital and Braidwell, established new positions during the second quarter.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report)'s share price traded down 5.1% on Monday. The stock traded as low as $26.69 and last traded at $26.69. 91,164 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 313,573 shares. The stock had previously closed at $28.13.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Wall Street Zen downgraded Avalyn Pharma from a "hold" rating to a "sell" rating in a report on Sunday, September 20th. Morgan Stanley increased their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Raymond James Financial initiated coverage on Avalyn Pharma in a research report on Friday. They issued an "outperform" rating and a $60.00 price objective on the stock. Finally, Weiss Ratings assumed coverage on Avalyn Pharma in a report on Thursday, August 13th. They issued a "sell (d+)" rating for the company. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $60.00.

Avalyn Pharma Price Performance

The stock has a market capitalization of $1.18 billion and a price-to-earnings ratio of -1.17. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. The stock has a 50-day moving average price of $33.49.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $0.05. Equities analysts expect that Avalyn Pharma Inc. will post -3.81 earnings per share for the current year.

Institutional Investors Weigh In On Avalyn Pharma

Several institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp purchased a new position in Avalyn Pharma during the second quarter valued at $10,501,000. Braidwell LP purchased a new stake in shares of Avalyn Pharma in the second quarter worth about $26,382,000. Montanova Capital LLC bought a new position in Avalyn Pharma during the second quarter valued at approximately $82,402,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Avalyn Pharma during the 2nd quarter worth approximately $1,321,000.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company's primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn's lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company's development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.